Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA, Frej MS, Rafa VM, Hansen UK, Ormhøj M, Tyron A, Jensen AWP, Kadivar M, Bentzen AK, Munk KK, Aasbjerg GN, Ternander JSH, Heeke C, Tamhane T, Schmess C, Funt SA, Kjeldsen JW, Kverneland AH, Met Ö, Draghi A, Jakobsen SN, Donia M, Marie Svane I, Hadrup SR. Tvingsholm SA, et al. Among authors: funt sa. J Immunother Cancer. 2023 Aug;11(8):e006847. doi: 10.1136/jitc-2023-006847. J Immunother Cancer. 2023. PMID: 37586765 Free PMC article.
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor.
Taylor J, Donoghue MT, Ho C, Petrova-Drus K, Al-Ahmadie HA, Funt SA, Zhang Y, Aypar U, Rao P, Chavan SS, Haddadin M, Tamari R, Giralt S, Tallman MS, Rampal RK, Baez P, Kappagantula R, Kosuri S, Dogan A, Tickoo SK, Reuter VE, Bosl GJ, Iacobuzio-Donahue CA, Solit DB, Taylor BS, Feldman DR, Abdel-Wahab O. Taylor J, et al. Among authors: funt sa. J Clin Invest. 2020 Dec 1;130(12):6668-6676. doi: 10.1172/JCI139682. J Clin Invest. 2020. PMID: 32897884 Free PMC article.
CTLA-4 antibodies: new directions, new combinations.
Funt SA, Page DB, Wolchok JD, Postow MA. Funt SA, et al. Oncology (Williston Park). 2014 Nov;28 Suppl 3:6-14. Oncology (Williston Park). 2014. PMID: 25387681 Free article. Review.
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, Wolchok JD, Iyer G, Bajorin DF, Callahan MK, Rosenberg JE. Teo MY, et al. J Clin Oncol. 2018 Jun 10;36(17):1685-1694. doi: 10.1200/JCO.2017.75.7740. Epub 2018 Feb 28. J Clin Oncol. 2018. PMID: 29489427 Free PMC article. Clinical Trial.
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.
Pianko MJ, Funt SA, Page DB, Cattry D, Scott EC, Ansell SM, Borrello IM, Gutierrez M, Lendvai N, Hassoun H, Landgren CO, Lesokhin AM. Pianko MJ, et al. Among authors: funt sa. Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30. Leuk Lymphoma. 2018. PMID: 28554253 Free PMC article. Clinical Trial. No abstract available.
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.
Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, Snyder A, Merghoub T, Wolchok JD, Nielsen M, Rosenberg JE, Bajorin DF, Hadrup SR. Holm JS, et al. Among authors: funt sa. Nat Commun. 2022 Apr 11;13(1):1935. doi: 10.1038/s41467-022-29342-0. Nat Commun. 2022. PMID: 35410325 Free PMC article. Clinical Trial.
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.
Borch A, Bjerregaard AM, Araujo Barbosa de Lima V, Østrup O, Yde CW, Eklund AC, Mau-Sørensen M, Barra C, Svane IM, Nielsen FC, Funt SA, Lassen U, Hadrup SR. Borch A, et al. Among authors: funt sa. Front Genet. 2023 Mar 23;14:1058605. doi: 10.3389/fgene.2023.1058605. eCollection 2023. Front Genet. 2023. PMID: 37035751 Free PMC article.
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition.
Borch A, Carri I, Reynisson B, Alvarez HMG, Munk KK, Montemurro A, Kristensen NP, Tvingsholm SA, Holm JS, Heeke C, Moss KH, Hansen UK, Schaap-Johansen AL, Bagger FO, de Lima VAB, Rohrberg KS, Funt SA, Donia M, Svane IM, Lassen U, Barra C, Nielsen M, Hadrup SR. Borch A, et al. Among authors: funt sa. Front Immunol. 2024 Apr 3;15:1360281. doi: 10.3389/fimmu.2024.1360281. eCollection 2024. Front Immunol. 2024. PMID: 38633261 Free PMC article.
81 results